Pulsatile intravenous insulin therapy: The best practice to reverse diabetes complications?

Medical Hypotheses

Volumn 73, Issue 3, 2009, Pages 363-369

  Reza Mirbolooki, M ^a   Taylor, George E ^b   Knutzen, Victor K ^c   Scharp, David W ^d   Willcourt, Robin ^b   Lakey, Jonathan R T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NorMedex   (United States)

^c PIVIT Centers International   (United States)

^d Prodo Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; INSULIN; INSULIN RECEPTOR; REPAGLINIDE; SULFONYLUREA;

ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG MECHANISM; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; RISK FACTOR;

DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; MODELS, BIOLOGICAL; PULSATILE FLOW;

EID: 67649577493     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.02.042     Document Type: Article

References (71)

1. Diabetes Atlas. 3rd ed. © International Diabetes Federation. Available from: ; 2006 [accessed 21.11.08].
2. CDC. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, CDC. Available from: ; 2005 [accessed 21.11.08].
3. Silink M. Childhood diabetes: a global perspective. Horm Res 57 Suppl 1 (2002) 1
4. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
5. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
6. Katsoyannis P.G. The chemical synthesis of human and sheep insulin. Am J Med 40 5 (1966) 652-661
7. Lang D.A., Matthews D.R., Peto J., and Turner R.C. Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N Engl J Med 301 (1979) 1023-1027
8. Aoki T.T., Grecu E.O., Arcangeli M.A., et al. Chronic intermittent intravenous insulin therapy: a new frontier in diabetes therapy. Diab Technol Therapeut 3 (2001) 111-123
9. Pørksen N., Munn S., Steers J., Veldhuis J.D., and Butler P.C. Impact of sampling technique on appraisal of pulsatile insulin secretion by deconvolution and cluster analysis. Am J Physiol 269 (1995) E1106-E1114
10. Pørksen N., Munn S., Steers J., et al. Pulsatile insulin secretion accounts for 70% of total insulin secretion during fasting. Am J Physiol 269 (1995) E478-E488
11. Goodner C.J., Walike B.C., Koerker D.J., et al. Insulin, glucagon, and glucose exhibit synchronous, sustained oscillations in fasting monkeys. Science 195 (1977) 177-179
12. Paolisso G., Sgambato S., Torella R., et al. Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet cell function in normal subjects and patients with type 1 diabetes. J Clin Endocrinol Metab 66 (1988) 1220-1226
13. Kerner W., Bruckel J., Zier H., et al. Similar effects of pulsatile and constant intravenous insulin delivery. Diab Res Clin Pract 4 (1988) 269-274
14. Stagner J.I., Samols E., and Weir G.C. Sustained oscillations of insulin, glucagon, and somatostatin from the isolated canine pancreas during exposure to a constant glucose concentration. J Clin Invest 65 (1980) 939-942
15. O'Meara N.M., Sturis J., Blackman J.D., et al. Oscillatory insulin secretion after pancreas transplant. Diabetes 42 (1993) 855-861
16. Bergsten P., and Hellman B. Glucose-induced amplitude regulation of pulsatile insulin secretion from individual pancreatic islets. Diabetes M42 (1993) 670-674
17. 2+ in the release of pancreatic islet hormones. Diab Metab 20 (1994) 123-131
18. 2+ in glucose-stimulated pancreatic beta-cells. Biochem J 314 (1996) 91-94
19. Trump B.F., and Berezesky I.K. Calcium-mediated cell injury and cell death. FASEB J 9 (1995) 219-228
20. Koopmans S.J., Sips H.C., Krans H.M., and Radder J.K. Pulsatile intravenous insulin replacement in streptozotocin diabetic rats is more efficient than continuous delivery: effects on glycaemic control, insulin-mediated glucose metabolism and lipolysis. Diabetologia 39 (1996) 391-400
21. Bratusch-Marrain P.R., Komjati M., and Waldhausl W.K. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans. Diabetes 35 (1986) 922-926
22. Sundsten T., Ortsäter H., and Bergsten P. Inhibition of intrapancreatic ganglia causes sustained and non-oscillatory insulin release from perfused pancreas (Abstract). Diabetologia 41 (1998) 76A
23. Kindmark H., Kohler M., Arkhammar P., et al. Oscillations in cytoplasmic free calcium concentration in human pancreatic islets from subjects with normal and impaired glucose tolerance. Diabetologia 37 (1994) 1121-1131
24. Lin J.M., Fabregat M.E., Gomis R., and Bergsten P. Pulsatile insulin release from islets isolated from three subjects with type 2 diabetes. Diabetes 51 (2002) 988-993
25. Bingley P.J., Matthews D.R., Williams A.J., Bottazzo G.F., and Gale E.A. Loss of regular oscillatory insulin secretion in islet cell antibody positive non-diabetic subjects. Diabetologia 35 (1992) 32-38
26. 2+ response to glucose as an indicator of impairment of the pancreatic beta-cell function. Eur J Clin Invest 20 Suppl 1 (1990) S10-S17
27. Mao C.S., Berman N., Roberts K., and Ipp E. Glucose entrainment of high-frequency plasma insulin oscillations in control and type 2 diabetic subjects. Diabetes 48 (1999) 714-721
28. Matthews D.R., Lang D.A., Burnett M.A., and Turner R.C. Control of pulsatile insulin secretion in man. Diabetologia 24 (1983) 231-237
29. Goodner C.J., Koerker D.J., Weigle D.S., and McCulloch D.K. Decreased insulin- and glucagon-pulse amplitude accompanying beta-cell deficiency induced by streptozotocin in baboons. Diabetes 38 (1989) 925-931
30. Wagman A.S., and Nuss J.M. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des 7 (2001) 417-450
31. Pørksen N., Munn S., Steers J., Veldhuis J.D., and Butler P.C. Effects of glucose ingestion versus infusion on pulsatile insulin secretion: the incretin effect is achieved by amplification of insulin secretory burst mass. Diabetes 45 (1996) 1317-1323
32. Porksen N.K., Munn S.R., Steers J.L., et al. Mechanisms of sulfonylurea's stimulation of insulin secretion in vivo: selective amplification of insulin secretory burst mass. Diabetes 45 (1996) 1792-1797
33. Pørksen N., Grofte B., Nyholm B., et al. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion. Diabetes 47 (1998) 45-49
34. Porksen N., Munn S.R., Steers J.L., Veldhuis J.D., and Butler P.C. Effects of somatostatin on pulsatile insulin secretion: elective inhibition of insulin burst mass. Am J Physiol 270 (1996) E1043-E1049
35. Hollingdal M., Sturis J., Gall M.A., et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in type 2 diabetes. Diab Med 22 (2005) 1408-1413
36. Juhl C.B., Pørksen N., Pincus S.M., et al. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes 50 (2001) 1778-1784
37. Ritzel R., Schulte M., Pørksen N., et al. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 50 (2001) 776-784
38. Claus T.H., Pan C.Q., Buxton J.M., et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J Endocrinol 192 (2007) 371-380
39. Banting F.G., Best C.H., Collip J.B., et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 12 (1922) 141-146
40. Hirsch I.B. Drug therapy insulin analogues. N Engl J Med 352 (2005) 174-183
41. Heller S.Rk., Amiel S.A., and Mansell P. Et al. Effects of fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diab Care 22 (1999) 1607-1611
42. Cefalu W.T. Evaluation of alternative strategies for optimizing glycemia: progress to date. Am J Med 113 (2002) 23S-35S
43. Sutherland D.E., Gruessner R.W., and Gruessner A.C. Pancreas transplantation for treatment of diabetes mellitus. World J Surg 25 (2001) 487-496
44. Polonsky K.S., Given B.D., Hirsch L., et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81 (1988) 435-441
45. Meier J.J., Hong-McAtee I., Galasso R., et al. Intrahepatic transplanted islets in humans secrete insulin in a coordinate pulsatile manner directly into the liver. Diabetes 55 (2006) 2324-2332
46. Ryan E.A., Paty B.W., Senior P.A., et al. Five-year follow-up after clinical islet transplantation. Diabetes 54 (2005) 2060-2069
47. Robertson R.P. Islet transplantation as a treatment for diabetes: a work in progress. N Engl J Med 350 (2004) 694-705
48. Marksman J.F., Rosen M., Siegel man E.S., et al. Magnetic resonance-defined per portal statuses following intraportal islet transplantation: a functional footprint of islet graft survival?. Diabetes 52 (2003) 1591-1594
49. Bhargava R., Senior P.A., Ackerman T.E., et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 53 (2004) 1311-1317
50. Francis I.R., Cohan R.H., McNulty N.J., et al. CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. Am J Radiol 180 (2003) 1217-1224
51. Aoki T.T., Grecu E.O., Gollapudi G.M., et al. Effect of intensive insulin therapy on progression of overt nephropathy in patients with type I diabetes mellitus. Endocr Pract 5 (1999) 174-178
52. Song S.H., McIntyre S.S., Shah H., et al. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab 85 (2000) 4491-4499
53. Vantyghem M.C., and Press M. Management strategies for brittle diabetes. Ann Endocrinol (Paris) 67 (2006) 287-296
54. Aoki T.T., Benbarka M.M., Okimura M.C., et al. Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus. Lancet 342 (1993) 515-518
55. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6 (2006) 479-483
56. Ayodele O.E., Alebiosu C.O., and Salako B.L. Diabetic nephropathy - a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 96 (2004) 1445-1454
57. Aoki T.T., Grecu E.O., Prendergast J.J., et al. Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy. Diab Care 18 (1995) 1260-1265
58. Sharma K., and Ziyadeh F.N. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor β as a key mediator. Diabetes 44 (1995) 1139-1146
59. Sima A.A. Pathological mechanisms involved in diabetic neuropathy: can we slow the process?. Curr Opin Invest Drugs 7 (2006) 324-337
60. Sima A.A., Zhang W., and Grunberger G. Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res 5 (2004) 65-77
61. Pierson C.R., Zhang W., Murakawa Y., and Sima A.A. Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J Neuropathol Exp Neurol 62 (2003) 260-271
62. Amar J., Chamontin B., Pelissier M., Garelli I., and Salvador M. Influence of glucose metabolism on nycthemeral blood pressure variability in hypertensives with an elevated waist-hip ratio. A link with arterial dispensability. Am J Hypertens 8 (1995) 426-428
63. Ikeda T., Matsubara T., Sato Y., and Sakamoto N. Circadian blood pressure variation in diabetic patients with autonomic neuropathy. J Hypertens 11 (1993) 581-587
64. Aoki TT, Grecu EO, Arcangeli MA, Meisenheimer R. Effect of intensive insulin therapy on abnormal circadian blood pressure pattern in patients with type I diabetes mellitus. Online J Curr Clin Trials. ;1995 [accessed 17.01.09].
65. Aoki T.T., Grecu E.O., and Arcangeli M.A. Chronic intermittent intravenous insulin therapy corrects orthostatic hypotension of diabetes. Am J Med 99 (1995) 683-684
66. Rutter G.A. Insulin secretion: feed-forward control of insulin biosynthesis?. Curr Biol 9 (1999) R443-R445
67. Persaud S.J., Muller D., and Jones P.M. Insulin signalling in islets. Biochem Soc Trans 36 (2008) 290-293
68. Kulkarni R.N., Bruning J.C., Winnay J.N., et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96 (1999) 329-339
69. Hunter S.J., Atkinson A.B., Ennis C.N., Sheridan B., and Bell P.M. Association between insulin secretory pulse frequency and peripheral insulin action in NIDDM and normal subjects. Diabetes 45 (1996) 683-686
70. Goodner C.J., Sweet I.R., and Harrison Jr. H.C. Rapid reduction and return of surface insulin receptors after exposure to brief pulses of insulin in perifused rat hepatocytes. Diabetes 37 (1988) 1316-1323
71. Xu G.G., and Rothenberg P.L. Insulin receptor signaling in the beta cell influences insulin gene expression and insulin content: evidence for autocrine beta-cell regulation. Diabetes 47 (1998) 1243-1252